Von Willebrand disease

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Von Willebrand disease | |
|---|---|
| Synonyms | vWD |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Bleeding, easy bruising, nosebleeds, heavy menstrual periods |
| Complications | Anemia, hemorrhage |
| Onset | Birth |
| Duration | Lifelong |
| Types | Type 1, Type 2 (2A, 2B, 2M, 2N), Type 3 |
| Causes | Genetic mutation in the VWF gene |
| Risks | Family history |
| Diagnosis | Blood test, genetic testing |
| Differential diagnosis | Hemophilia, platelet function disorder |
| Prevention | None |
| Treatment | Desmopressin, factor VIII concentrates, antifibrinolytics |
| Medication | Desmopressin, tranexamic acid |
| Prognosis | Generally good with treatment |
| Frequency | 1 in 100 to 1 in 10,000 |
| Deaths | Rare |
A common inherited bleeding disorder
Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of the von Willebrand factor (VWF), a protein that is crucial for blood clotting. It is the most common hereditary bleeding disorder in humans, affecting approximately 1% of the population. VWD is named after Erik Adolf von Willebrand, the Finnish physician who first described the condition in 1926.
Pathophysiology[edit]
Von Willebrand factor is a large multimeric glycoprotein that plays a key role in hemostasis. It mediates the adhesion of platelets to sites of vascular injury and stabilizes factor VIII, another important clotting protein. In VWD, the deficiency or dysfunction of VWF leads to impaired platelet adhesion and secondary deficiency of factor VIII, resulting in a bleeding tendency.
Types[edit]
VWD is classified into three main types based on the quantitative and qualitative defects of VWF:
Type 1[edit]
Type 1 VWD is the most common form, accounting for approximately 70-80% of all cases. It is characterized by a partial quantitative deficiency of VWF. Patients with type 1 VWD usually have mild to moderate bleeding symptoms.
Type 2[edit]
Type 2 VWD is a qualitative defect of VWF and is further divided into subtypes 2A, 2B, 2M, and 2N, each with distinct functional abnormalities of the VWF molecule. Type 2 VWD accounts for about 15-20% of cases.
Type 3[edit]

Type 3 VWD is the most severe form and is characterized by a near-complete absence of VWF. It is inherited in an autosomal recessive manner and is associated with severe bleeding episodes.
Symptoms[edit]
The symptoms of VWD vary depending on the type and severity of the disease. Common symptoms include:
- Easy bruising
- Frequent nosebleeds
- Bleeding gums
- Heavy menstrual bleeding (menorrhagia)
- Prolonged bleeding from cuts
- Excessive bleeding after surgery or dental work
Diagnosis[edit]
The diagnosis of VWD involves a combination of clinical evaluation and laboratory tests. Key tests include:
- Measurement of VWF antigen levels
- VWF activity assays (e.g., ristocetin cofactor activity)
- Factor VIII activity
- Multimer analysis to assess the structure of VWF
Treatment[edit]
Treatment of VWD depends on the type and severity of the disease. Options include:
- Desmopressin (DDAVP), which stimulates the release of VWF from endothelial cells
- VWF replacement therapy using plasma-derived concentrates
- Antifibrinolytic agents such as tranexamic acid
- Hormonal therapy for menorrhagia
Prognosis[edit]
With appropriate management, individuals with VWD can lead normal lives. However, they may need to take precautions to avoid situations that could lead to bleeding.
See also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian